SCHEMBL15701231

SCHEMBL15701231

COc1ccc(CC(=O)Nc2ccc(NC(=O)c3cscn3)cc2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
GRM4 Q14833 2/20 0.54
EPHX2 P34913 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
LMNA P02545 4/20 0.50
TP53 P04637 2/20 0.50
USP2 O75604 2/20 0.46
MAPT P10636 4/20 0.46
ANO1 Q5XXA6 1/20 0.45
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
POLB P06746 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MAPK1 P28482 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701232 0.85 ANO1 (0.57) GRM4SMN1; SMN2LMNAMAPTANO1
SCHEMBL15701096 0.80 USP2 (0.60) ALDH1A1GRM4SMN1; SMN2LMNAUSP2
SCHEMBL28826499 0.78 KDM4E (0.67) ALDH1A1GRM4SMN1; SMN2LMNATP53
SCHEMBL15701228 0.78 SMN1; SMN2 (0.50) GRM4SMN1; SMN2LMNATP53MAPT
SCHEMBL15701287 0.78 LMNA (0.65) ALDH1A1EPHX2SMN1; SMN2LMNAMAPT
SCHEMBL15701091 0.77 SMN1; SMN2 (0.56) SMN1; SMN2LMNAMAPTANO1HSD17B10
SCHEMBL28020698 0.75 ALDH1A1 (0.65) ALDH1A1EPHX2SMN1; SMN2LMNAMAPT
SCHEMBL15701265 0.74 PSEN1 (0.50) GRM4LMNAMAPTANO1
SCHEMBL15701108 0.74 PSEN1 (0.57) GRM4LMNAMAPTANO1MAPK1
SCHEMBL15701036 0.74 CSNK1D (0.52) LMNAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914592-B1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INT (DE) 2017-10-11 EP disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
WO-2014070979-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS CDKN1A, CCNA1, IFNAR1 ALDH1A1 2565/4885GRM4 4020/4885EPHX2 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.